The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Development of Yondelis® (trabectedin, ET-743). A semisynthetic process solves the supply problem
Abstract
Ecteinascidins are marine natural products consisting of two or three linked tetrahydroisoquinoline subunits and an active carbinolamine functional group. Their potent antiproliferative activity against a variety of tumor cells makes them attractive candidates for development as anticancer agents. The lead compound, Yondelis (trabectedin, ET-743) is the first marine anticancer agent approved in the European Union for patients with soft tissue sarcoma (STS). Positive results of a large randomized Phase III clinical trial in ovarian cancer have recently been presented. The low amounts present in its natural source, the tunicate Ecteinascidia turbinata, made it necessary to develop efficient synthetic procedures. The original total synthesis is reviewed as well as a new semisythetic process from the readily available cynosafracin B, which has solved the supply problem.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ingenta (1965) · Cited by 5,382
Stille, J. K. (1986) · Angewandte Chemie International Edition in English · doi:10.1002/anie.198605081 · Cited by 3,394
Dess, D. B., & Martin, J. C. (1991) · Journal of the American Chemical Society · doi:10.1021/ja00019a027 · Cited by 2,090
Chemistry and Biology of the Tetrahydroisoquinoline Antitumor Antibiotics
Scott, J. D., & Williams, R. M. (2002) · Chemical Reviews · doi:10.1021/cr010212u · Cited by 1,149
Rinehart, K. L., Holt, T. G., Fregeau, N. L., Stroh, J. G., Keifer, P. A., Sun, F., Li, L. H., & Martin, D. G. (1990) · The Journal of Organic Chemistry · doi:10.1021/jo00302a007 · Cited by 492
Enantioselective Total Synthesis of Ecteinascidin 743
Corey, E. J., Gin, D. Y., & Kania, R. S. (1996) · Journal of the American Chemical Society · doi:10.1021/ja962480t · Cited by 352
Takebayashi, Y., Pourquier, P., Zimonjic, D. B., Nakayama, K., Emmert, S., Ueda, T., Urasaki, Y., Kanzaki, A., Akiyama, S.-I., Popescu, N., et al. (2001) · Nature Medicine · doi:10.1038/91008 · Cited by 348
On the Mechanism of the Phenyl Isothiocyanate Degradation of Peptides.
Edman, P., Lindberg, B., Waterman, H. I., Eliasson, N. A., & Thorell, B. (1956) · Acta Chemica Scandinavica · doi:10.3891/acta.chem.scand.10-0761 · Cited by 320
Pommier, Y., Kohlhagen, G., Bailly, C., Waring, M., Mazumder, A., & Kohn, K. W. (1996) · Biochemistry · doi:10.1021/bi960306b · Cited by 303
A method for the regiospecific synthesis of enol triflates by enolate trapping
Mc Murry, J. E., & Scott, W. J. (1983) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)81581-6 · Cited by 285
Synthesis of Ecteinascidin ET-743 and Phthalascidin Pt-650 from Cyanosafracin B
Cuevas, C., Pérez, M., Martín, M. J., Chicharro, J. L., Fernández-Rivas, C., Flores, M., Francesch, A., Gallego, P., Zarzuelo, M., de la Calle, F., et al. (2000) · Organic Letters · doi:10.1021/ol0062502 · Cited by 282
Self-citationAntitumor tetrahydroisoquinoline alkaloids from the colonial ascidian Ecteinascidia turbinata
Wright, A. E., Forleo, D. A., Gunawardana, G. P., Gunasekera, S. P., Koehn, F. E., & McConnell, O. J. (1990) · The Journal of Organic Chemistry · doi:10.1021/jo00302a006 · Cited by 268
Ecteinascidin 743: A Minor Groove Alkylator That Bends DNA toward the Major Groove
Zewail-Foote, M., & Hurley, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990241l · Cited by 214
Martinez, E. J., Owa, T., Schreiber, S. L., & Corey, E. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3496 · Cited by 170
Herrero, A. B., Martín-Castellanos, C., Marco, E., Gago, F., & Moreno, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0179 · Cited by 170
Sakai, R., Rinehart, K. L., Guan, Y., & Wang, A. H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.23.11456 · Cited by 167
Taamma, A., Misset, J. L., Riofrio, M., Guzmán, C., Brain, E. G. C., Lázaro, L. L., Rosing, H., Jimeno, J. M., & Cvitkovic, E. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1256 · Cited by 161
Soares, D. G., Escargueil, A. E., Poindessous, V., Sarasin, A. R., de Gramont, A., Bonatto, D., Henriques, J. A. P., & Larsen, A. K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609877104 · Cited by 156
Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action
Aune, G. J., Furuta, T., & Pommier, Y. G. (2002) · Anti-Cancer Drugs · doi:10.1097/00001813-200207000-00001 · Cited by 129
Valoti, G., Nicoletti, M. I., Pellegrino, A., Jimeno, J. M., Hendriks, H. R., D’Incalci, M., Faircloth, G. T., & Giavazzi, R. (1998) · PubMed · Cited by 127
Role of homologous recombination in trabectedin-induced DNA damage
Tavecchio, M., Simone, M., Erba, E., Chiolo, I., Liberi, G., Foiani, M., D’Incalci, M., & Damia, G. L. M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.01.003 · Cited by 98
Thiol-reactive fluorescent probes for protein labelling
Corrie, J. E. T. (1994) · Journal of the Chemical Society Perkin Transactions 1 · doi:10.1039/p19940002975 · Cited by 95
Xeroderma pigmentosum genes: Functions inside and outside DNA repair
Sugasawa, K. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm282 · Cited by 83
Villalona-Calero, M. A., Eckhardt, S. G., Weiss, G. R., Hidalgo, M. M., Beijnen, J. H., van Kesteren, C., Rosing, H., Campbell, E., Kraynak, M. A., Lázaro, L. L., et al. (2002) · PubMed · Cited by 82
Preclinical and clinical results with the natural marine product ET-743
D’Incalci, M., & Jimeno, J. M. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.11.1843 · Cited by 72
Guan, Y., Sakai, R., Rinehart, K. L., & Wang, A. H. ‐. (1993) · PubMed · Cited by 71
ET-743: a novel agent with activity in soft-tissue sarcomas
Fayette, J., Ray-Coquard, I. L., Alberti, L., Boyle, H. J., Méeus, P., Decouvelaere, A., Thiesse, P., Sunyach, M., Ranchère‐Vince, D., & Blay, J. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000228740.70379.3f · Cited by 66
Unique Features of the Mode of Action of ET-743
D’Incalci, M., Erba, E., Damia, G. L. M., Galliera, E., Carrassa, L., Marchini, S., Mantovani, R., Tognon, G., Fruscio, R., Jimeno, J. M., et al. (2002) · The Oncologist · doi:10.1634/theoncologist.7-3-210 · Cited by 46
Cited by
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
The odyssey of marine pharmaceuticals: a current pipeline perspective
Mayer, A. M. S., Glaser, K. B., Cuevas, C., Jacobs, R. S., Kem, W., Little, R. D., McIntosh, J. M., Newman, D. J., Potts, B. C., & Shuster, D. E. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.02.005 · Cited by 666
Self-citationThe pharmaceutical industry and natural products: historical status and new trends
David, B., Wolfender, J.-L., & Dias, D. A. (2015) · Phytochemistry Reviews · doi:10.1007/s11101-014-9367-z · Cited by 579
Harnessing tumor‐associated macrophages as aids for cancer immunotherapy
Li, X., Liu, R., Su, X., Pan, Y., Han, X., Shao, C., & Shi, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1102-3 · Cited by 364
Natural products for human health: an historical overview of the drug discovery approaches
Bernardini, S., Tiezzi, A., Laghezza Masci, V., & Ovidi, E. (2018) · Natural Product Research · doi:10.1080/14786419.2017.1356838 · Cited by 355
Metadata
- Authors
- Cuevas, C., & Francesch, A.
- Venue
- Natural Product Reports
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2009
- Volume
- 26
- Issue
- 3
- Pages
- 322
- ISSN
- 0265-0568 (ISSN-L)
- 1460-4752
- OpenAlex
- W2163685688
- Cited by
- 323
- References
- 28
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
